206 related articles for article (PubMed ID: 30367145)
21. [Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer].
Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):624-628. PubMed ID: 32867452
[TBL] [Abstract][Full Text] [Related]
22. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
23. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
24. Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism.
Ni Q; Ji H; Zhao Z; Fan X; Xu C
Eur J Pharmacol; 2009 Jul; 614(1-3):1-6. PubMed ID: 19389394
[TBL] [Abstract][Full Text] [Related]
25. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
Chen X; Yang Y; Berger I; Khalid U; Patel A; Cai J; Farwell MD; Langer C; Aggarwal C; Albelda SM; Katz SI
Oncotarget; 2017 Apr; 8(15):24213-24223. PubMed ID: 27655645
[TBL] [Abstract][Full Text] [Related]
26. Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth.
Li XQ; Shang BY; Wang DC; Zhang SH; Wu SY; Zhen YS
Cancer Lett; 2011 Feb; 301(2):212-20. PubMed ID: 21216091
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
Spigel DR; Hainsworth JD; Joseph MJ; Shipley DL; Hagan MK; Thompson DS; Burris HA; Greco FA
Cancer; 2018 May; 124(9):1982-1991. PubMed ID: 29451696
[TBL] [Abstract][Full Text] [Related]
28. Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor.
Zhang L; Liu Z; Yang K; Kong C; Liu C; Chen H; Huang J; Qian F
Mol Pharm; 2017 Dec; 14(12):4705-4713. PubMed ID: 29068216
[TBL] [Abstract][Full Text] [Related]
29. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
Qin RS; Zhang ZH; Zhu NP; Chen F; Guo Q; Hu HW; Fu SZ; Liu SS; Chen Y; Fan J; Han YW
BMC Cancer; 2018 Oct; 18(1):967. PubMed ID: 30305062
[TBL] [Abstract][Full Text] [Related]
30. The use of bevacizumab in non-small cell lung cancer: an update.
Lauro S; Onesti CE; Righini R; Marchetti P
Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680
[TBL] [Abstract][Full Text] [Related]
31. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
32. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].
Wang X; Zhang W; Du W; Zhang X; Ren X; Cao S
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):761-768. PubMed ID: 29167006
[TBL] [Abstract][Full Text] [Related]
34. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
Zhang D; Zhang C; Huang J; Guan Y; Guo Q
Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
[TBL] [Abstract][Full Text] [Related]
35. Bronchoscopic intratumoral injections of cisplatin and endostar as concomitants of standard chemotherapy to treat malignant central airway obstruction.
Jiang W; Yang X; Wang X; Li Y; Yang X; Wang N; Yin B
Postgrad Med J; 2022 Feb; 98(1156):104-112. PubMed ID: 33070116
[TBL] [Abstract][Full Text] [Related]
36. Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis.
Wang Y; Ren H
BMC Cancer; 2024 Feb; 24(1):187. PubMed ID: 38331776
[TBL] [Abstract][Full Text] [Related]
37. [Combining bevacizumab with endostatin gets better antitumor efficacy in vivo in lung cancer animal model].
Niu N; Li B; Liu C; Hu Y; Li X; Li J; Shi H; Zhang H
Zhongguo Fei Ai Za Zhi; 2013 Feb; 16(2):61-6. PubMed ID: 23425896
[TBL] [Abstract][Full Text] [Related]
38. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
Wu F; Zhang S; Xiong A; Gao G; Li W; Cai W; Su C; Chen X; Zhou F; Zhao J; Ren S; Zhou C
Clin Lung Cancer; 2018 Nov; 19(6):e831-e842. PubMed ID: 30026059
[TBL] [Abstract][Full Text] [Related]
39. Changes of activated circulating endothelial cells and survivin in patients with non-small cell lung cancer after antiangiogenesis therapy.
Wang J; Huang C; Wei XY; Qi DL; Gong LQ; Mu HY; Yao Q; Li K
Chin Med J (Engl); 2008 Nov; 121(22):2234-40. PubMed ID: 19080323
[TBL] [Abstract][Full Text] [Related]
40. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
